BETHESDA, Md., Dec. 21, 2015 /PRNewswire/ -- Northwest
Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology
company developing DCVax® personalized immune therapies for solid
tumor cancers, announced today the results of its 2015 Annual
Shareholder Meeting, held on Friday,
December 18, 2015. There were three matters subject to
a shareholder vote: the re-election of Linda Powers and Dr. Navid Malik as Directors for 3-year terms, and
the re-appointment of the Company's auditors, Marcum LLP. NW
Bio has a staggered Board, with one or two of the current five
Directors up for re-election each year, and with each election
being for a 3-year term.
Ms. Powers was re-elected with over 82% of the vote, Dr. Malik
was re-elected with over 80% of the vote and Marcum was
re-appointed with over 85% of the vote.
"We greatly appreciate the high turnout and the strong support
from our shareholders," commented Linda
Powers, CEO. "The support is particularly gratifying
after the waves of false and misleading attacks upon the Company
and its Directors and Managers personally, in recent months, many
of them anonymous. Such attacks divert Company time,
attention and resources. Despite this, we remain committed to
our mission, and in March, May and September we reported
encouraging data from our DCVax-L and DCVax-Direct programs.
We also look forward to making more progress in the New Year."
"We encourage any interested parties to review the most recent
data from both programs that was presented on September 16 and that can be found in slides 21,
37 and 38 of the slide deck on the home page of the Company's
website (www.nwbio.com)."
"We are very pleased that Dr. Malik is willing to serve for
another 3-year term, as we believe his expertise in the biotech and
pharma sector is of great value for NW Bio. I, too, am
looking forward to serving another term on NW Bio's Board as we
work toward bringing our DCVax treatments to patients with some of
the most lethal cancers, who need new and better treatment
options."
About Northwest Biotherapeutics
Northwest Biotherapeutics is a biotechnology company focused on
developing personalized immunotherapy products designed to treat
cancers more effectively than current treatments, without
toxicities of the kind associated with chemotherapies, and on a
cost-effective basis, in both the United
States and Europe. The Company has a broad platform
technology for DCVax dendritic cell-based vaccines. The
Company's lead program is a 348-patient Phase III trial in newly
diagnosed Glioblastoma multiforme (GBM), which is on a partial
clinical hold in regard to new screening of patients. GBM is the
most aggressive and lethal form of brain cancer, and is an "orphan
disease." The Company is under way with a 60-patient Phase
I/II trial with DCVax-Direct for all types of inoperable solid
tumors cancers. It has completed enrollment in the Phase I
portion of the trial. The Company previously conducted a
Phase I/II trial with DCVax-L for metastatic ovarian cancer
together with the University of
Pennsylvania. The Company previously received
clearance from the FDA for a 612-patient Phase III trial in
prostate cancer. In Germany,
the Company has received approval of a 5-year Hospital Exemption
for the treatment of all gliomas (primary brain cancers) outside
the clinical trial.
Disclaimer
Statements made in this news release that are not historical
facts, including statements concerning future treatment of patients
using DCVax and future clinical trials, are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "expect," "believe,"
"intend," "design," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify
forward-looking statements. Actual results may differ
materially from those projected in any forward-looking
statement. Specifically, there are a number of important
factors that could cause actual results to differ materially from
those anticipated, such as risks related to the Company's ongoing
ability to raise additional capital, risks related to the Company's
ability to enroll patients in its clinical trials and complete the
trials on a timely basis, uncertainties about the clinical trials
process, uncertainties about the timely performance of third
parties, risks related to whether the Company's products will
demonstrate safety and efficacy, risks related to the Company's and
Cognate's abilities to carry out the intended manufacturing and
expansions contemplated in the Cognate Agreements, risks related to
the Company's ability to carry out the Hospital Exemption program
and risks related to possible reimbursement and pricing.
Additional information on these and other factors, including Risk
Factors, which could affect the Company's results, is included in
its Securities and Exchange Commission ("SEC") filings.
Finally, there may be other factors not mentioned above or included
in the Company's SEC filings that may cause actual results to
differ materially from those projected in any forward-looking
statement. You should not place undue reliance on any
forward-looking statements. The Company assumes no obligation
to update any forward-looking statements as a result of new
information, future events or developments, except as required by
securities laws.
Logo -
http://photos.prnewswire.com/prnh/20110329/SF73084LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nw-bio-announces-annual-meeting-results-re-election-of-directors-300195867.html
SOURCE Northwest Biotherapeutics